

IN THE CLAIMS:

Please amend the claims to read:

Claims 1-27. (Canceled)

28. (Withdrawn) An antibody or fragment thereof that specifically binds a polypeptide comprising an amino acid sequence as set forth in any of SEQ ID NO: 13, SEQ ID NO: 15, OR SEQ ID NO: 17.

29. (Withdrawn) An antibody of claim 28 which is a monoclonal antibody.

30. (Canceled)

31. (Withdrawn) A pharmaceutical composition comprising a therapeutically effective amount of an antibody of Claim 28 in a mixture with a pharmaceutically acceptable adjuvant, carrier, solubilizer, or diluent.

Claims 32-35. (Canceled)

36. (Withdrawn) The antibody or fragment thereof of claim 28, which is a chimeric antibody.

37. (Withdrawn) The antibody or fragment thereof of claim 28, which is a CDR-grafted antibody.

38. (Previously presented) A monoclonal antibody or fragment thereof that binds a polypeptide consisting of an amino acid sequence selected from:

(a) amino acids 1 to 524 of SEQ ID NO: 11,

(b) amino acids 1 to 547 of SEQ ID NO: 13, and

(c) amino acids 1 to 547 of SEQ ID NO: 15.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

39. (Previously presented) A monoclonal antibody or fragment thereof of claim 38, wherein the antibody or fragment thereof binds a polypeptide consisting of amino acids 1 to 524 of SEQ ID NO: 11.

40. (Previously presented) The antibody or fragment thereof of claim 38, which is a chimeric antibody.

41. (Previously presented) The antibody or fragment thereof of claim 38, which is a CDR-grafted antibody.

42. (Previously presented) A monoclonal antibody or fragment thereof that binds a polypeptide comprising an amino acid sequence as set forth in SEQ ID NO: 11.

43. (Currently amended) A ~~pharmaceutical~~ composition comprising an antibody of claim 42 in a mixture with ~~a pharmaceutically acceptable~~ an adjuvant, carrier, solubilizer, or diluent.

44. (Previously presented) The antibody or fragment thereof of claim 42 which is a chimeric antibody.

45. (Previously presented) The antibody or fragment thereof of claim 42 which is a CDR-grafted antibody.

46. (Currently amended) A ~~pharmaceutical~~ composition comprising an antibody of claim 38 in a mixture with ~~a pharmaceutically acceptable~~ an adjuvant, carrier, solubilizer, or diluent.

47. (Currently amended) An antibody or fragment thereof which is raised against ~~at least a portion of~~ a polypeptide comprising SEQ ID NO: 11, ~~wherein the portion is not identical to any portion of Cek5.~~

48. (Previously presented) The antibody of claim 47 which is a monoclonal antibody.
49. (Previously presented) The antibody of claim 47 which is a chimeric antibody.
50. (Previously presented) The antibody of claim 47 which is a CDR-grafted antibody.
51. (Currently amended) A ~~pharmaceutical~~ composition comprising an antibody of claim 47 in a mixture with a ~~pharmaceutically acceptable~~ an adjuvant, carrier, solubilizer, or diluent.
52. (Currently amended) An antibody or fragment thereof which is raised against ~~at least a portion of~~ amino acids 1 to 524 of SEQ ID NO: 11.
53. (Previously presented) The antibody of claim 52 which is a monoclonal antibody.
54. (Previously presented) The antibody of claim 52 which is a chimeric antibody.
55. (Previously presented) The antibody of claim 52 which is a CDR-grafted antibody.
56. (Currently amended) A ~~pharmaceutical~~ composition comprising an antibody of claim 52 in a mixture with a ~~pharmaceutically acceptable~~ an adjuvant, carrier, solubilizer, or diluent.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com